Celldex Therapeutics, Inc. Earnings

Celldex Therapeutics, Inc.’s revenue fell -71.56% since last year same period to $1.18Mn in the Q4 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -63.18% fall in its revenue since last 3-months.

Celldex Therapeutics, Inc.’s net profit fell -8.74% since last year same period to $-47.09Mn in the Q4 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -11.8% fall in its net profits since last 3-months.

Celldex Therapeutics, Inc.’s net profit margin fell -282.31% since last year same period to -4007.83% in the Q4 2024. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -203.62% fall in its net profit margins since last 3-months.

Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.69 - a 3.44% jump from last quarter’s estimates.

Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.69.

Celldex Therapeutics, Inc.’s earning per share (EPS) jumped 14.46% since last year same period to -0.71 in the Q4 2024. This indicates that the Celldex Therapeutics, Inc. has generated 14.46% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Celldex Therapeutics, Inc.’s return on assets (ROA) stands at -0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Celldex Therapeutics, Inc.’s return on equity (ROE) stands at -0.27.